Unaudited Financial Result for 31st December, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma reported nil revenue from operations, with total income of ₹6.45 lakh for Q3 FY26 coming entirely from 'other income,' versus ₹0.30 lakh in Q3 FY25. The company swung to a profit after tax of ₹3.92 lakh in Q3 FY26 from a loss of ₹6.20 lakh a year ago. For the nine-month period, total income nearly doubled to ₹112.19 lakh (from ₹57.40 lakh), while PAT rose to ₹72.17 lakh from ₹38.81 lakh. However, the statutory auditor issued a disclaimer of opinion, flagging inability to verify the end-use of funds raised via preferential allotment, uncertainty around related-party transactions, lack of documentation for advances/deposits, and non-compliance with GST and TDS filing/deposit requirements.
Despite the improved headline numbers, the auditor's disclaimer of opinion severely undermines confidence in the reported figures. Concerns over fund usage, related-party dealings, and tax non-compliance could weigh on the stock and pose governance risks for shareholders.